Lista de obras - Sylvie Freeman - Dominio Público Uruguay

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

artículo científico publicado en 2018

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

scientific article published on 02 September 2016

A novel role for PECAM-1 (CD31) in regulating haematopoietic progenitor cell compartmentalization between the peripheral blood and bone marrow ⬇️

artículo científico publicado en 2008

An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts

artículo científico publicado en 2015

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting

scientific article published on 02 April 2020

Assessment of Minimal Residual Disease in Standard-Risk AML.

artículo científico publicado en 2016

Assessment of minimal residual disease in acute myeloid leukemia

artículo científico publicado en 2010

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

artículo científico publicado en 2012

Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.

artículo científico publicado en 2003

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

artículo científico publicado en 2019

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

artículo científico publicado en 2014

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

artículo científico publicado en 2014

Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31

artículo científico publicado en 1999

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia

artículo científico publicado en 2016

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

artículo científico publicado en 2016

Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias

artículo científico publicado en 2003

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults

scientific article published on 05 December 2018

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

artículo científico publicado en 2013

MRD evaluation of AML in clinical practice: are we there yet?

scientific article published on 01 December 2019

MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia.

artículo científico publicado en 2012

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

artículo científico publicado en 2018

Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.

artículo científico publicado en 2018

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

scientific article published on 01 February 2020

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

artículo científico publicado en 2017

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia

artículo científico publicado en 2016

Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer

artículo científico publicado en 2006

Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.

artículo científico publicado en 2008

Professor David Grimwade (1962-2016)

scientific article published on 16 January 2017

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

artículo científico publicado en 2013

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia

artículo científico publicado en 2014

Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes

artículo científico publicado en 2009

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

artículo científico publicado en 2019

Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.

artículo científico publicado en 2005

T Cell Subset Enumeration and Weekend HIV Clinics: Reliable Performance of CD4 Cell Counts after 3 Days

article

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2

artículo científico publicado en 1999

Lista de obras de Sylvie Freeman

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

A novel role for PECAM-1 (CD31) in regulating haematopoietic progenitor cell compartmentalization between the peripheral blood and bone marrow ⬇️

An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blasts

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting

Assessment of Minimal Residual Disease in Standard-Risk AML.

Assessment of minimal residual disease in acute myeloid leukemia

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

Characterization of Siglec-5 (CD170) expression and functional activity of anti-Siglec-5 antibodies on human phagocytes.

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP and phospholipase C-gamma1 with PECAM-1/CD31

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia

Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

MRD evaluation of AML in clinical practice: are we there yet?

MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia

Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer

Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.

Professor David Grimwade (1962-2016)

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia

Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.

T Cell Subset Enumeration and Weekend HIV Clinics: Reliable Performance of CD4 Cell Counts after 3 Days

The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2